Evidence map›Paper›PMID 34561166›Full record

ReviewParkinsonism & related disorders2021

Seeking progress in disease modification in Parkinson disease.

Codrin Lungu, Jesse M Cedarbaum, Ted M Dawson, E Ray Dorsey, Carlos Faraco, Howard J Federoff, Brian Fiske, Robert Fox, Andrew M Goldfine, Karl Kieburtz and 13 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Parkinsonism & related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 14 institutions in 2 countries.

Codrin LunguDivision of Clinical Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd, #2188, Rockville, MD, 20852, USA. Electronic address: lunguci@ninds.nih.gov.
Jesse M CedarbaumCoeruleus Clinical Sciences LLC, Woodbridge, CT, USA.
Ted M DawsonJohns Hopkins University School of Medicine, Baltimore, MD, USA.
E Ray DorseyUniversity of Rochester Medical Center, Rochester, NY, USA.
Carlos FaracoDivision of Clinical Research, NINDS, NIH, Bethesda, MD, USA.
Howard J FederoffUniversity of California, Irvine, Irvine, CA, USA.
Brian FiskeThe Michael J Fox Foundation for Parkinson's Research, New York, NY, USA.
Robert FoxNeurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Andrew M GoldfineGlaxoSmithKline, Upper Providence, PA, USA.
Karl KieburtzUniversity of Rochester Medical Center, Rochester, NY, USA.
Eric A MacklinMassachusetts General Hospital, Boston, MA, USA.
Helen MatthewsThe Cure Parkinson's Trust, London, UK.
Gary RafaloffPatient Research Advocate, New York, NY, USA.
Rachel Saunders-PullmanDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nina F SchorNINDS, NIH, Bethesda, MD, USA.
Michael A SchwarzschildMassachusetts General Hospital, Boston, MA, USA.
Beth-Anne SieberDivision of Neuroscience, NINDS, NIH, Bethesda, MD, USA.
Tanya SimuniNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Dalton J SurmeierNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Amir TamizDivision of Translational Research, NINDS, NIH, Bethesda, MD, USA.
Milton H WernerInhibikase Therapeutics, Inc, Atlanta, GA, USA.
Clinton B WrightDivision of Clinical Research, NINDS, NIH, Bethesda, MD, USA.
Richard WyseThe Cure Parkinson's Trust, London, UK.
National Institutes of Health · USCure Parkinson's Trust · GBMassachusetts General Hospital · USNorthwestern University · USUniversity of Rochester Medical Center · USCleveland Clinic · USIcahn School of Medicine at Mount Sinai · USInhibikase Therapeutics (United States) · USJohns Hopkins University · USMichael J. Fox Foundation · USOffice of Extramural Research · USPatient Advocate Foundation · USProvidence College · USUniversity of California, Irvine · US

Funding

Dissecting Oligogenic Biomarkers in Ashkenazi Jews with Parkinson DiseaseU01NS107016 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI OZELIUS, LAURIE J., SAUNDERS-PULLMAN, RACHEL · 2019 to 2023
$6.6M
Dopaminergic and Muscarinic Signaling in the StriatumR01NS034696 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SURMEIER, DALTON JAMES · 1996 to 2018
$4.3M
Determinants of Basal Ganglia Pathology in Parkinson's DiseaseR01NS121174 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BEVAN, MARK D, SURMEIER, DALTON JAMES · 2021 to 2025
$3.6M
Intramural NIH HHS Z99 OD999999NINDS NIH HHS R01 NS034696NINDS NIH HHS R01 NS121174NINDS NIH HHS U01 NS107016
6 · The paper itself

Abstract

objectiveDisease modification in Parkinson disease (PD) has remained an elusive goal, in spite of large investments over several decades. Following a large meeting of experts, this review article discusses the state of the science, possible reasons for past PD trials' failures to demonstrate disease-modifying benefit, and potential solutions.

methodsThe National Institute of Neurological Disorders and Stroke (NINDS) convened a meeting including leaders in the field and representatives of key stakeholder groups to discuss drug therapy with the goal of disease modification in PD.

resultsImportant lessons can be learned from previous attempts, as well as from other fields. The selection process for therapeutic targets and agents differs among various organizations committed to therapeutic development. The areas identified as critical to target in future research include the development of relevant biomarkers, refinements of the targeted patient populations, considerations of novel trial designs, and improving collaborations between all stakeholders.

conclusionsWe identify potential barriers to progress in disease modification for Parkinson's and propose a set of research priorities that may improve the likelihood of success.

Indexed as

Drug DiscoveryBiomarkersHumansNational Institute of Neurological Disorders and Stroke (U.S.)Parkinson DiseaseUnited StatesBiomarkersClinical trialDisease modificationParkinsonPharmacotherapy

Identifiers

PMID34561166
PMCPMC11770554
OpenAlexW3199957798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.